ACST - the extra commentary with lots of details about the Phase 3 trial sounded positive; 68% of patients already treated, and no delay of results expected. Mkt likes to hear that... Amazing that it recovered so much on such a big down day for biotechs and markets in general.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.